Fresh analysis suggests that people who discontinue blockbuster weight-loss injections like Mounjaro or Wegovy may regain shed pounds at a significantly accelerated pace than those who halt traditional diet and exercise programs.
Published data in a major medical journal points out that while obese individuals frequently drop a large proportion of their body weight while undergoing treatment, the weight is regained at an estimated rate of 0.8 kg per month once they quit.
"People purchasing such drugs should be aware of the potential of quick rebound weight gain when the treatment is stopped," cautioned researcher Dr. Susan Jebb.
Such speed of regain means a reversion to starting weight within about a year and a half.
Analyzing Therapies
The study, which examined 37 of trials involving over 9,000 of participants, compared the results of GLP-1 agonists with conventional dieting.
The team emphasize that individuals who shed pounds through diet and exercise typically have a more gradual weight regain—approximately 0.1 kg a month—once they finish.
Understanding the Rapid Rebound
Experts believe the way of the drugs is key to understanding the heightened weight return.
GLP-1 drugs mimic a natural hormone called glucagon-like peptide-1, which moderates appetite.
"Artificially providing GLP-1 levels several times higher than normal could lead to the body to produce less of its own natural GLP-1, and may also reduce sensitivity to its effects," explained Dr. Adam Collins, a nutrition researcher.
"Withdrawal of this GLP-1 'fix' results in hunger is unsuppressed, making overeating much more probable."
An Ongoing Condition?
The NHS recommend the injections for individuals with weight-linked medical conditions, accompanied by recommended lifestyle changes.
Many experts say that, due to the likelihood of relapse, the therapy might need to be long-term.
This perspective is reinforced by drug manufacturers, who state that the results "underscore the persistent nature of obesity," comparing it to managing conditions like diabetes.
User Testimonies
People who have discontinued the jabs report a sudden return of cravings.
"It felt as if something flipping and you become extremely hungry," recalled an individual.
This difficulty is compounded if users have not developed lasting dietary or behavioural changes during treatment.
Widespread Use
Figures show that millions of people in the UK have used weight-loss jabs in the last 12 months, with demand continuing to grow.
- Adoption is greater among women compared to males.
- The 40s and 50s demographic shows the greatest usage rates.
- A large proportion access the drugs through private healthcare rather than the NHS.
In conclusion, clinicians emphasize that while GLP-1 drugs are potent tools for shedding pounds, they are not a standalone fix and long-term success relies on integrated lifestyle changes.
